Stock Events

Stock Events

Actinogen Medical Limited 

€0.02
6
+€0+5.56% Wednesday 06:12

Statistics

Day High
0.02
Day Low
0.02
52W High
0.05
52W Low
0.01
Volume
-
Avg. Volume
-
Mkt Cap
60.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q1 2023
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.01
-0
-0
0
Expected EPS
N/A
Actual EPS
-0.003374020282608084

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-16.76MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3AC.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company is involved in the development of drugs that target central nervous system disorders, including Alzheimer's, similar to Actinogen's focus.
Biogen
BIIB
Mkt Cap22.63B
Biogen Inc. focuses on neurodegenerative diseases and has multiple products in Alzheimer's disease treatment, directly competing with Actinogen's Xanamem.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a strong portfolio in developing treatments for Alzheimer's disease, which competes with Actinogen's therapeutic areas.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. specializes in Alzheimer's disease treatments using sigma-1 receptor agonists, a similar area of neurological focus.
AC Immune SA
ACIU
Mkt Cap340.03M
AC Immune SA develops therapies for Alzheimer's disease, directly competing with Actinogen's approach to cognitive impairment.
Athira Pharma Inc
ATHA
Mkt Cap16.39M
Athira Pharma focuses on restoring neuronal health and function, similar to Actinogen's approach in treating Alzheimer's disease.
Acumen Pharmaceuticals
ABOS
Mkt Cap133.87M
Acumen Pharmaceuticals, Inc. is directly involved in Alzheimer's disease research, targeting amyloid beta oligomers, a common target in Alzheimer's therapy.

About

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Show more...
CEO
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.
Country
AU
ISIN
AU000000ACW3
WKN
000A0MZH8

Listings

OTC Link
US
ATGGF
F
DE
3AC.F
AU
AU
ACW.AU

0 Comments

Share your thoughts

FAQ

What is Actinogen Medical Limited stock price today?▼
The current price of 3AC.F is €0.02 EUR — it has increased by +5.56% in the past 24 hours. Watch Actinogen Medical Limited stock price performance more closely on the chart.
What is Actinogen Medical Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Actinogen Medical Limited stocks are traded under the ticker 3AC.F.
Is Actinogen Medical Limited stock price growing?▼
3AC.F stock has risen by +0% compared to the previous week, the month change is a -5% fall, over the last year Actinogen Medical Limited has showed a +5.56% increase.
What is Actinogen Medical Limited market cap?▼
Today Actinogen Medical Limited has the market capitalization of 60.55M
When is the next Actinogen Medical Limited earnings date?▼
Actinogen Medical Limited is going to release the next earnings report on August 31, 2026.
What were Actinogen Medical Limited earnings last quarter?▼
3AC.F earnings for the last quarter are -0 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Actinogen Medical Limited revenue for the last year?▼
Actinogen Medical Limited revenue for the last year amounts to 0 EUR.
What is Actinogen Medical Limited net income for the last year?▼
3AC.F net income for the last year is -16.76M EUR.
In which sector is Actinogen Medical Limited located?▼
Actinogen Medical Limited operates in the Health Care sector.
When did Actinogen Medical Limited complete a stock split?▼
The last stock split for Actinogen Medical Limited was on December 06, 2017 with a ratio of 17:15.
Where is Actinogen Medical Limited headquartered?▼
Actinogen Medical Limited is headquartered in Sydney, AU.